FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. U.S. Food and Drug Administration. News release: FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma. 2018 Nov 28.
2. European Medicines Agency. European public assessment report summary for the public: Truxima (rituximab). 2017 Aug 3.
3. Genovese MC, Kalunian KC, Walker D, et al. Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic DMARDs [abstract]. Arthritis Rheumatol. 2018 Oct; 70 (suppl 10).